- Home
- ATAI vs HURA Comparison
ATAI vs HURA Comparison
Compare ATAI & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATAI | HURA |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 131.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATAI | HURA |
|---|---|---|
| Price | $4.19 | $0.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $14.33 | $11.50 |
| AVG Volume (30 Days) | ★ 3.2M | 599.4K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,018,000.00 | N/A |
| Revenue This Year | $943.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 811.78 | N/A |
| 52 Week Low | $1.15 | $0.70 |
| 52 Week High | $6.75 | $5.50 |
Technical Indicators
Market Signals| Indicator | ATAI | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 27.10 |
| Support Level | $3.88 | $0.81 |
| Resistance Level | $4.72 | $1.07 |
| Average True Range (ATR) | 0.25 | 0.16 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 35.71 | 8.60 |
Price Performance
Historical ComparisonAbout ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.